Theriva Biologics, Inc. (TOVX) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 4, 2026, Theriva Biologics, Inc. (TOVX) trades at a price-to-earnings ratio of -0.0x, with a stock price of $0.18 and trailing twelve-month earnings per share of $-2.71.
Compared to the Healthcare sector median P/E of 23.3x, TOVX trades at a 100% discount to its sector peers. The sector includes 225 companies with P/E ratios ranging from 0.0x to 190.3x.
Relative to the broader market, TOVX trades at a notable discount to the S&P 500 median P/E of 26.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our TOVX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
See TOVX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TOVX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare TOVX vs AGIO
See how TOVX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is TOVX stock overvalued or undervalued?
TOVX current P/E: -0.0x. 5-year average P/E: N/A. Percentile: N/A.
How does TOVX's valuation compare to peers?
Theriva Biologics, Inc. P/E of -0.0x compares to sector median of 23.3x. Sector comparison provides relative valuation context.
What is TOVX's PEG ratio?
TOVX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.